{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:36:59Z","timestamp":1774064219193,"version":"3.50.1"},"reference-count":39,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>RE-EMBARK investigated etanercept (ETN) withdrawal and retreatment in patients with nonradiographic axial spondyloarthritis (nr-axSpA) achieving inactive disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients received ETN and a background nonsteroidal antiinflammatory drug for 24 weeks in period 1 (P1); those achieving inactive disease (Ankylosing Spondylitis Disease Activity Score [ASDAS] with C-reactive protein [CRP] &lt; 1.3) discontinued ETN for 40 weeks or less (period 2 [P2]). Patients who flared (ASDAS with erythrocyte sedimentation rate [ESR] \u2265 2.1) were retreated for 12 weeks in period 3 (P3). The primary endpoint was the proportion of patients with inactive disease who flared within 40 weeks of ETN withdrawal. Baseline characteristics were analyzed post hoc as predictors of maintenance and regaining of inactive disease, respectively, using univariate logistic and stepwise multivariable logistic regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The proportion of patients experiencing flare following ETN withdrawal (P2) increased from 22.3% (25\/112) after 4 weeks to 67% (77\/115) after 40 weeks; 74.8% (86\/115) experienced flare at any time during P2. Median time to flare was 16.1 weeks. Most patients (54\/87, 62.1%) who were retreated with ETN in P3 reachieved inactive disease. Absence of both sacroiliitis detected on magnetic resonance imaging (MRI) and high-sensitivity CRP (hs-CRP) &gt; 3 mg\/L at baseline predicted inactive disease maintenance in P2 following ETN withdrawal in multivariable analysis; male sex and age younger than 40 years predicted regaining of inactive disease in P3 after flare\/retreatment. There were no unexpected safety signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Approximately 25% of patients maintained inactive disease for 40 weeks after discontinuing ETN. Absence of both MRI sacroiliitis and high hs-CRP at baseline predicted response maintenance after ETN withdrawal. (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02509026\">NCT02509026<\/jats:ext-link>)<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.220353","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T13:20:12Z","timestamp":1668518412000},"page":"478-487","source":"Crossref","is-referenced-by-count":6,"title":["Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip","family":"Van den Bosch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-7635","authenticated-orcid":false,"given":"Francisco J.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanbo","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3827-3787","authenticated-orcid":false,"given":"Cecilia","family":"Borlenghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-6063","authenticated-orcid":false,"given":"Vassilis","family":"Tsekouras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-7493","authenticated-orcid":false,"given":"Bonnie","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"2023122109250657000_50.4.478.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket244"},{"key":"2023122109250657000_50.4.478.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2023122109250657000_50.4.478.3","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13510"},{"key":"2023122109250657000_50.4.478.4","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023122109250657000_50.4.478.5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023122109250657000_50.4.478.6","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2023122109250657000_50.4.478.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207596"},{"key":"2023122109250657000_50.4.478.8","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/acr.23276","article-title":"Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis: 104-week results from a randomized, placebo-controlled study","volume":"69","author":"Dougados","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2023122109250657000_50.4.478.9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001108"},{"key":"2023122109250657000_50.4.478.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201010"},{"key":"2023122109250657000_50.4.478.11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaad.2009.10.046","article-title":"Intermittent etanercept therapy in pediatric patients with psoriasis","volume":"63","author":"Siegfried","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2023122109250657000_50.4.478.12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/rheumatology\/kex457","article-title":"Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort","volume":"57","author":"Yahya","year":"2018","journal-title":"Rheumatology"},{"key":"2023122109250657000_50.4.478.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.04.005"},{"key":"2023122109250657000_50.4.478.14","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/rheumatology\/kez657","article-title":"Predicting response to anti-TNF\u03b1 therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS","volume":"59","author":"Macfarlane","year":"2020","journal-title":"Rheumatology"},{"key":"2023122109250657000_50.4.478.15","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s10067-020-05319-6","article-title":"Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review","volume":"40","author":"Zurita Prada","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2023122109250657000_50.4.478.16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13075-021-02650-4","article-title":"Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol","volume":"23","author":"Maksymowych","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2023122109250657000_50.4.478.17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000917"},{"key":"2023122109250657000_50.4.478.18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/acr.24442","article-title":"Performance and predictors of minimal disease activity response in patients with peripheral spondyloarthritis treated with adalimumab","volume":"74","author":"Coates","year":"2022","journal-title":"Arthritis Care Res"},{"key":"2023122109250657000_50.4.478.19","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-015-0620-4"},{"key":"2023122109250657000_50.4.478.20","doi-asserted-by":"crossref","first-page":"876040","DOI":"10.1155\/2015\/876040","article-title":"Predictive factors of clinical response of infliximab therapy in active nonradiographic axial spondyloarthritis patients","volume":"2015","author":"Lin","year":"2015","journal-title":"Biomed Res Int"},{"key":"2023122109250657000_50.4.478.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211313"},{"key":"2023122109250657000_50.4.478.22","first-page":"884","article-title":"Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis","volume":"36","author":"Lian","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2023122109250657000_50.4.478.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2023122109250657000_50.4.478.24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13075-019-1873-3","article-title":"Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study","volume":"21","author":"Moreno","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023122109250657000_50.4.478.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31362-X"},{"key":"2023122109250657000_50.4.478.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.4182"},{"key":"2023122109250657000_50.4.478.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.3824"},{"key":"2023122109250657000_50.4.478.28","doi-asserted-by":"publisher","DOI":"10.1186\/ar3369"},{"key":"2023122109250657000_50.4.478.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081048"},{"key":"2023122109250657000_50.4.478.30","doi-asserted-by":"crossref","first-page":"iv38","DOI":"10.1093\/rheumatology\/keaa543","article-title":"Sex and gender differences in axial spondyloarthritis: myths and truths","volume":"59","author":"Rusman","year":"2020","journal-title":"Rheumatology"},{"key":"2023122109250657000_50.4.478.31","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/1756-185X.12885","article-title":"Is there any gender-specific difference in the cut-off values of ankylosing spondylitis disease activity score in patients with axial spondyloarthritis?","volume":"20","author":"Kilic","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2023122109250657000_50.4.478.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520290060030"},{"key":"2023122109250657000_50.4.478.33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-013-2372-6","article-title":"Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients","volume":"33","author":"De Stefano","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2023122109250657000_50.4.478.34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratacos","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023122109250657000_50.4.478.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204882"},{"key":"2023122109250657000_50.4.478.36","first-page":"174","article-title":"Patient-tailored dose reduction of TNF-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice","volume":"33","author":"Arends","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2023122109250657000_50.4.478.37","doi-asserted-by":"crossref","first-page":"e0168958","DOI":"10.1371\/journal.pone.0168958","article-title":"Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondylitis","volume":"11","author":"Park","year":"2016","journal-title":"PLoS One"},{"key":"2023122109250657000_50.4.478.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205202"},{"key":"2023122109250657000_50.4.478.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.1322"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T17:27:34Z","timestamp":1703179654000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,1]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.3899\/jrheum.220353"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220353","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]}}}